Tumour-specific arginine vasopressin promoter activation in small-cell lung cancer

Abstract

Small-cell lung cancer (SCLC) can produce numerous mitogenic neuropeptides, which are not round in normal respiratory epithelium. Arginine vascopressin is detected in up to two-thirds of SCLC tumours whereas normal physiological expression is fssentialy restricted to the hypothalamus. This presents the opportunity to identify elements of the gene promote: which could be exploited for SCLC-specific targeting. A series of human vasopressin 5' promoter fragments (1048 bp, 468 bp and 199 bp) were isolated and cloned upstream of a reporter gene. These were transfected into a panel of ten cell lines, including SCLC with high or low endogenous vasopressin transcription, non-SCLC and bronchial epithelium. All these fragments directed reporter gene expression in the five SCLC cell lines, but had negligible activity in the control lines. The level of reporter gene expression reflected the level or endogenous, vasopressin production, with up to 4.9-fold (s.d. 0.34) higher activity than an SV40 promoter. The elements required for this strong, restricted, SCLC-specific promoter activity are contained within the 199-bp fragment. Further analysis of this region indicated involvement of E-box transcription factor binding sites; although tumour-specificity was retained by a 65-bp minimal promoter fragment. These data show that a short region of the vasopressin promoter will drive strong expression in SCLC in vitro and raise the possibility of targeting gene therapy to these tumours.